Utilidad de la midodrina para controlar el síncope vasovagal: ¿la recomienda la evidencia?
Usefulness of Midodrine for the Control of Recurrent Vasovagal Syncope: Does the Evidence Recommend it?
Barra lateral del artículo
PDF (English)
FLIP
XML (English)
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Contenido principal del artículo
Resumen
Introducción: El síncope vasovagal es la principal causa de pérdida transitoria de la conciencia, y es un motivo de consulta cada vez más frecuente en pediatría y medicina del adulto. La midodrina es un agonista de los receptores alfa, de acción periférica, empleada principalmente en el manejo de la hipotensión ortostática; sin embargo, también se ha evaluado en el síncope vasovagal, con resultados prometedores. Objetivo: Analizar la evidencia más reciente sobre la utilidad de la midodrina para el control y la prevención del síncope vasovagal. Materiales y métodos: Se realizó una búsqueda bibliográfica utilizando términos de búsqueda como Vasovagal Syncope y Midodrine, así como sinónimos, que se combinaron con operadores booleanos, en cinco bases de datos, hasta octubre del 2022. Se incluyeron estudios originales, revisiones sistemá- ticas y metanálisis, publicados tanto en inglés como en español. Resultados: Ensayos controlados aleatorizados y revisiones sistemáticas y metanálisis difieren ligeramente entre resultados, pero estos demuestran un efecto global protector. La evidencia más reciente y completa indica que utilizar este agente reduce significativamente la positividad al realizar la prueba de la mesa inclinada y que previene la aparición de episodios sincopales. Conclusiones: Aunque la evidencia actual sobre la eficacia de la midodrina respecto a la prevención y control del síncope vasovagal es limitada, se observa un efecto protector significativo, porque disminuye el riesgo de sufrir un episodio sincopal, aproximadamente hasta en un 50%.
Palabras clave:
Descargas
Detalles del artículo
Referencias (VER)
Hatoum T, Raj S, Sheldon RS. Current approach to the treatment of vasovagal syncope in adults. Intern Emerg Med. 2022. https://doi.org/10.1007/s11739-022-03102-w DOI: https://doi.org/10.1007/s11739-022-03102-w
Tao C, Cui Y, Zhang C, Liu X, Zhang Q, Liu P, et al. Clinical Efficacy of Empirical Therapy in Children with Vasovagal Syncope. Children (Basel). 2022; 9(7):1065. https://doi.org/10.3390/children9071065 DOI: https://doi.org/10.3390/children9071065
Sheldon RS, Sheldon AG, Connolly SJ, Morillo CA, Klingenheben T, Krahn AD, et al. Age of first faint in patients with vasovagal syncope. J Cardiovasc Electrophysiol. 2006; 17(1):49-54. https://doi.org/10.1111/j.1540-8167.2005.00267.x DOI: https://doi.org/10.1111/j.1540-8167.2005.00267.x
Deveau AP, Sheldon R, Maxey C, Ritchie D, Doucette S, Parkash R. Sex Differences in Vasovagal Syncope: A Post Hoc Analysis of the Prevention of Syncope Trials (POST) I and II. Can J Cardiol. 2020; 36(1):79-83. https://doi.org/10.1016/j.cjca.2019.10.008 DOI: https://doi.org/10.1016/j.cjca.2019.10.008
Aydin MA, Salukhe TV, Wilke I, Willems S. Management and therapy of vasovagal syncope: A review. World J Cardiol. 2010; 2(10):308-15. https://doi.org/10.4330/wjc.v2.i10.308 DOI: https://doi.org/10.4330/wjc.v2.i10.308
Vaddadi G, Corcoran SJ, Esler M. Management strategies for recurrent vasovagal syncope. Intern Med J. 2010; 40(8):554-60. https://doi.org/10.1111/j.1445-5994.2010.02295.x DOI: https://doi.org/10.1111/j.1445-5994.2010.02295.x
Raj SR, Coffin ST. Medical therapy and physical maneuvers in the treatment of the vasovagal syncope and orthostatic hypotension. Prog Cardiovasc Dis. 2013; 55(4):425-33. https://doi.org/10.1016/j.pcad.2012.11.004 DOI: https://doi.org/10.1016/j.pcad.2012.11.004
Malave B, Vrooman B. Vasovagal Reactions during Interventional Pain Management Procedures-A Review of Pathophysiology, Incidence, Risk Factors, Prevention, and Management. Med Sci (Basel). 2022; 10(3):39. https://doi.org/10.3390/medsci10030039 DOI: https://doi.org/10.3390/medsci10030039
Atici A, Asoglu R, Demirkiran A, Serbest NG, Emektas B, Sarikaya R, et al. The relationship between clinical characteristics and psychological status and quality of life in patients with vasovagal syncope. North Clin Istanb. 2020; 7(3):237-245. https://doi.org/10.14744/nci.2020.93753 DOI: https://doi.org/10.14744/nci.2020.93753
Ng J, Sheldon RS, Ritchie D, Raj V, Raj SR. Reduced quality of life and greater psychological distress in vasovagal syncope patients compared to healthy individuals. Pacing Clin Electrophysiol. 2019; 42(2):180-188. https://doi.org/10.1111/pace.13559 DOI: https://doi.org/10.1111/pace.13559
Alhuzaimi A, Aljohar A, Alhadi AN, Aljenedil A, Hersi AS. Psychiatric traits in patients with vasovagal and unexplained syncope. Int J Gen Med. 2018; 11:99-104. https://doi.org/10.2147/IJGM.S157335 DOI: https://doi.org/10.2147/IJGM.S157335
Carretero Colomer M. Midodrina. Offarm. 2008; 27(4):112-113. Disponible en: https://www.elsevier.es/es-revista-offarm-4-articulo-midodrina-13120074
Lei LY, Raj SR, Sheldon RS. Midodrine for the prevention of vasovagal syncope: a systematic review and meta-analysis. 2022; EP Europace. 24(7):1171–1178- https://doi.org/10.1093/europace/euab323 DOI: https://doi.org/10.1093/europace/euab323
Jeanmonod R, Sahni D, Silberman M. Vasovagal Episode. [Updated 2022 Jul 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470277/
Jardine DL, Wieling W, Brignole M, Lenders JWM, Sutton R, Stewart J. The pathophysiology of the vasovagal response. Heart Rhythm. 2018; 15(6):921-929. https://doi.org/10.1016/j.hrthm.2017.12.013 DOI: https://doi.org/10.1016/j.hrthm.2017.12.013
Gert van Dijk J, van Rossum IA, Thijs RD. The pathophysiology of vasovagal syncope: Novel insights. Autonomic Neuroscience. 2021; 236:102899. https://doi.org/10.1016/j.autneu.2021.102899 DOI: https://doi.org/10.1016/j.autneu.2021.102899
Benditt DG, Gert van Dijk J, Krishnappa D, Adkisson WO, Sakaguchi S. Neurohormones in the Pathophysiology of Vasovagal Syncope in Adults. Front Cardiovasc Med. 2020; 7:76. https://doi.org/10.3389/fcvm.2020.00076 DOI: https://doi.org/10.3389/fcvm.2020.00076
Stewart JM, Medow MS, Sutton R, Visintainer P, Jardine DL, Wieling W. Mechanisms of Vasovagal Syncope in the Young: Reduced Systemic Vascular Resistance Versus Reduced Cardiac Output. J Am Heart Assoc. 2017; 6(1):e004417. https://doi.org/10.1161/JAHA.116.004417 DOI: https://doi.org/10.1161/JAHA.116.004417
Wieling W, Jardine DL, de Lange FJ, Brignole M, Nielsen HB, Stewart J, et al. Cardiac output and vasodilation in the vasovagal response: An analysis of the classic papers. Heart Rhythm. 2016; 13(3):798-805. https://doi.org/10.1016/j.hrthm.2015.11.023 DOI: https://doi.org/10.1016/j.hrthm.2015.11.023
Malamud-Kessler C, Bruno E, Chiquete E, Sentíes-Madrid H, Campos-Sánchez M. Pathophysiology of neurally-mediated syncope. Neurología (English Edition). 2016; 31(9):620-627. https://doi.org/10.1016/j.nrleng.2014.04.015 DOI: https://doi.org/10.1016/j.nrleng.2014.04.015
Hainsworth R. Pathophysiology of syncope. Clinical Autonomic Research. 2004; 14(S-1):I/18–I/24. https://doi.org/10.1007/s10286-004-1004-2 DOI: https://doi.org/10.1007/s10286-004-1004-2
Gelman S, Mushin PS. Catecholamine-induced changes in the splanchnic circulation affecting systemic hemodynamics. Anesthesiology. 2004; 100:434–439. https://doi.org/10.1097/00000542-200402000-00036 DOI: https://doi.org/10.1097/00000542-200402000-00036
Zhang R, Behbehani K, Crandall C, Zuckerman J, Levine B. Dynamic regulation of heart rate during acute hypotension: new insight into baroreflex function. Am J Physiol Heart Circ Physiol. 2000; 280:H407–H419. https://doi.org/10.1152/ajpheart.2001.280.1.H407 DOI: https://doi.org/10.1152/ajpheart.2001.280.1.H407
Ocon A, Medow M, Taneja I, Stewart J. Respiration drives phase synchronization between blood pressure and RR interval following loss of cardiovagal baroreflex during vasovagal syncope. Am J Physiol Heart Circ Physiol. 2010; 300:H527–H540. https://doi.org/10.1152/ajpheart.00257.2010 DOI: https://doi.org/10.1152/ajpheart.00257.2010
Iwase S, Mano T, Kamiya A, Niimi Y, Qi Fu, Suzumura A. Syncopal attack alters the burst properties of muscle sympathetic nerve activity in humans. Auton Neurosci. 2002; 95:141–145. https://doi.org/10.1016/s1566-0702(01)00362-9 DOI: https://doi.org/10.1016/S1566-0702(01)00362-9
de Jong-de Vos van Steenwijk CCE, Wieling W, Harms MPM, Wesseling KH. Variability of nearfainting responses in healthy 6–16-year-old subjects. Clin Sci (Lond). 1997; 93:205–211. https://doi.org/10.1042/cs0930205 DOI: https://doi.org/10.1042/cs0930205
Fu Q, Verheyden B, Wieling W, Levine BD. Cardiac output and sympathetic vasoconstrictor responses during upright tilt to presyncope in healthy humans. J Physiol. 2012; 590:1839–1848. https://doi.org/10.1113/jphysiol.2011.224998 DOI: https://doi.org/10.1113/jphysiol.2011.224998
Brignole M, Rivasi G, Sutton R, Kenny RA, Morillo CA, Sheldon R, et al. Low-blood pressure phenotype underpins the tendency to reflex syncope. J Hypertens. 2021 ;39(7):1319-1325. https://doi.org/10.1097/HJH.0000000000002800 DOI: https://doi.org/10.1097/HJH.0000000000002800
Sutton R, Brignole M. Twenty-eight years of research permit reinterpretation of tilt-testing: hypotensive susceptibility rather than diagnosis. Eur Heart J. 2014; 35(33):2211-2. https://doi.org/10.1093/eurheartj/ehu255 DOI: https://doi.org/10.1093/eurheartj/ehu255
Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018; 39(21):1883-1948. https://doi.org/10.1093/eurheartj/ehy037 DOI: https://doi.org/10.1093/eurheartj/ehy037
Qingyou Z, Junbao D, Chaoshu T. The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope. J Pediatr. 2006; 149(6):777-80. https://doi.org/10.1016/j.jpeds.2006.07.031 DOI: https://doi.org/10.1016/j.jpeds.2006.07.031
Romme JJ, van Dijk N, Go-Schön IK, Reitsma JB, Wieling W. Effectiveness of midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial). Europace. 2011;
(11):1639-47. https://doi.org/10.1093/europace/eur200 DOI: https://doi.org/10.1093/europace/eur200
Sheldon R, Faris P, Tang A, Ayala-Paredes F, Guzman J, Marquez M, et al. Midodrine for the Prevention of Vasovagal Syncope : A Randomized Clinical Trial. Ann Intern Med. 2021; 174(10):1349-1356. https://doi.org/10.7326/M20-5415 DOI: https://doi.org/10.7326/M20-5415
Bagrul D, Ece I, Yılmaz A, Atik F, Kavurt AV. Midodrine treatment in children with recurrent vasovagal syncope. Cardiol Young. 2021; 31(5):817-821. https://doi.org/10.1017/S1047951120004746 DOI: https://doi.org/10.1017/S1047951120004746
Jorge JG, Raj SR, Teixeira PS, Teixeira JAC, Sheldon RS. Likelihood of injury due to vasovagal syncope: a systematic review and meta-analysis. Europace. 2021; 23(7):1092-1099. https://doi.org/10.1093/europace/euab041 DOI: https://doi.org/10.1093/europace/euab041
Aminorroaya A, Tavolinejad H, Sadeghian S, Jalali A, Alaeddini F, Emkanjoo Z, et al. Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial. Am Heart J. 2021; 237:5-
https://doi.org/10.1016/j.ahj.2021.03.002 DOI: https://doi.org/10.1016/j.ahj.2021.03.002
Lozada-Martinez ID, Suarez-Causado A, Solana-Tinoco JB. Ethnicity, genetic variants, risk factors and cholelithiasis: The need for eco-epidemiological studies and genomic analysis in Latin American surgery. Int J Surg. 2022; 99:106589. https://doi.org/10.1016/j.ijsu.2022.106589 DOI: https://doi.org/10.1016/j.ijsu.2022.106589
Mass-Hernández LM, Acevedo-Aguilar LM, Lozada-Martínez ID, Osorio-Agudelo LS, Maya-Betancourth JGEM, Paz-Echeverry OA, et al. Undergraduate research in medicine: A summary of the evidence on problems, solutions and outcomes. Ann Med Surg (Lond). 2022; 74:103280. https://doi.org/10.1016/j.amsu.2022.103280 DOI: https://doi.org/10.1016/j.amsu.2022.103280
Lozada-Martínez ID, Díaz-Castillo OJ, Pearson-Arrieta AC, Galeano-Buelvas A, Moscote-Salazar LR. Post-COVID 19 neurological syndrome: A new risk factor that modifies the prognosis of patients with dementia. Alzheimers Dement. 2022; 18(3):542-543. https://doi.org/10.1002/alz.12459 DOI: https://doi.org/10.1002/alz.12459
Rodríguez-Hernández YA, Villamizar-Gómez FJ, Mantilla-Pardo JC, Robledo-Arias JS, Rahman S, Lozada-Martinez ID, et al. Post-COVID 19 neurological syndrome: The need to define a cut-off score between the acute and post-COVID 19 phases. Ann Med Surg (Lond). 2021; 71:102983. https://doi.org/10.1016/j.amsu.2021.102983 DOI: https://doi.org/10.1016/j.amsu.2021.102983
Lozada-Martinez ID, Pava-Barrios GA, Yoli-Garrido A, Leal-Buitrago A, Rodriguez-Medina N. Post-COVID-19 cardiovascular syndrome: What does the evidence tell us?. J Pract Cardiovasc Sci 2022; 8:65-7. https://doi.org/10.4103/jpcs.jpcs_69_21 DOI: https://doi.org/10.4103/jpcs.jpcs_69_21
Lozada-Martinez ID, Torres-Llinás DM, Moscote-Salazar LR. Myocardial lesion in patients with COVID-19: Not all is in the lung. J Taibah Univ Med Sci. 2021; 16(2):303-304. https://doi.org/10.1016/j.jtumed.2021.01.006 DOI: https://doi.org/10.1016/j.jtumed.2021.01.006
Zimmermann T, du Fay de Lavallaz J, Nestelberger T, Gualandro DM, Lopez-Ayala P, Badertscher P, et al. International Validation of the Canadian Syncope Risk Score: A Cohort Study. Ann Intern Med. 2022; 175(6):783-794. https://doi.org/10.7326/M21-2313 DOI: https://doi.org/10.7326/M21-2313
Xia G, Jin JF, Ye Y, Wang XD, Hu B, Pu JL. The effects of ALDH2 Glu487Lys polymorphism on vasovagal syncope patients undergoing head-up tilt test supplemented with sublingual nitroglycerin. BMC Cardiovasc Disord. 2022; 22(1):451. https://doi.org/10.1186/s12872-022-02901-5 DOI: https://doi.org/10.1186/s12872-022-02901-5
Wang Y, Wang Y, He B, Tao C, Han Z, Liu P, et al. Plasma human growth cytokines in children with vasovagal syncope. Front Cardiovasc Med. 2022; 9:1030618. https://doi.org/10.3389/fcvm.2022.1030618 DOI: https://doi.org/10.3389/fcvm.2022.1030618
Li L, Zhao H, Ma X, Jiao F, Lin J. Calcitonin gene-related peptide predicts therapeutic response to midodrine hydrochloride in children with vasovagal syncope. Front Neurosci. 2022; 16:1026539. https://doi.org/10.3389/fnins.2022.1026539 DOI: https://doi.org/10.3389/fnins.2022.1026539
Raj SR, Sheldon RS. Vasovagal syncope: Treat the patient, and not just the disease. Auton Neurosci. 2022; 243:103035. https://doi.org/10.1016/j.autneu.2022.103035 DOI: https://doi.org/10.1016/j.autneu.2022.103035
Titov B, Matveeva N, Kulakova O, Baulina N, Bazyleva E, Kheymets G, et al. Vasovagal Syncope Is Associated with Variants in Genes Involved in Neurohumoral Signaling Pathways. Genes (Basel). 2022; 13(9):1653. https://doi.org/10.3390/genes13091653 DOI: https://doi.org/10.3390/genes13091653
Wang C, Chen L, Sun C, Zhang Y, Cao C, Ma Y, et al. Prevention of Blood Donation-related Vasovagal Response by Applied Muscle Tension: a Meta-analysis. J Int Med Res. 2022; 50(9):3000605221121958. https://doi.org/10.1177/03000605221121958 DOI: https://doi.org/10.1177/03000605221121958
Lazurova Z, Mitro P, Popovnakova M. The Role of Adenosine and Its Degradation Enzymes - Adenosinedeaminase and Adenosinekinase in Pathogenesis of Vasovagal Syncope. Eur J Intern Med. 2022; 105:77-81. https://doi.org/10.1016/j.ejim.2022.08.037 DOI: https://doi.org/10.1016/j.ejim.2022.08.037
Citado por
